China has a lucrative market for fake research reagents. Some scientists are fighting back.
Published in Nature | News Feature 10 May 2017
By Alan DoveSep. 14, 2017 , 2:00 PM
Commercially produced antibodies have become workhorses of basic research, but opaque supply chains, a lack of clear quality standards, and scientists’ complacency have turned antibody-based experiments into potential disaster zones. Several strategies can help researchers navigate past these pitfalls.